Based on the overexpression and oncogenic function of KDM2B in systemic cancers that contain cancer stem cells (Kottakis et al., 2014; Tzatsos et al., 2013; Ueda et al., 2015), we investigated KDM2B as a molecular target in glioblastoma. This evidence concerns the gene KDM2B and cancer.